baber/WOPTO huggingface dataset:
Patent DE-69227200-D1 (DE)
Inventor: JOERGENSEN PER
IPC: C07K1/14
Filed: 1992-12-11
Granted: 1998-11-05
Abstract: A process for the microbial production of a protein susceptible to inactivation in a fluid production medium by continuously and reversibly protecting said protein against said inactivation during the production stage, separating the protein from the production medium, deprotecting the protein, and recovering the protein product. The process is especially useful for obtaining substantially increased yields of the protein in question by continuously precipitating said protein.
Patent DE-69229552-D1 (DE)
Inventor: ANGELASTRO MICHAEL
IPC: A61K38/00
Filed: 1992-04-21
Granted: 1999-08-12
Abstract: Novel compounds which are chemically linked inhibitors of the proteases Elastase and Cathepsin G prevent connective tissue degradation associated with neutrophil induced inflammatory disease.
Patent DE-69232909-D1 (DE)
Inventor: SHAPIRO HOWARD K
IPC: A61K8/46
Filed: 1992-02-21
Granted: 2003-03-06
Abstract: The invention regards a novel use of pharmaceutical compositions in treating symptoms of disorders relating to neurological diseases and for treating pathophysiologically related symptomology in other body tissues, including peripheral neuropathies, secondary symptomology of diabetes, Alzheimer's disease, Parkinson's disease, alcoholic polyneuropathy and age-onset symptomology. Covalent bond crosslinking of protein and lipid subcellular elements appears to underlie the formation of polymerized aggregates of neurofilaments, other structural proteins and lipofuscin. The use of certain compounds may compete with cellular protein and lipid amine groups for reaction with disease-induced carbonyl-containing aliphatic and aromatic hydrocarbons. Such derivatized pharmacological agents can then be excreted by the kidneys, thus removing the toxic agent(s). The presence of an acid functional group on the agent used facilitates kidney recognition and removal. Another application of the present invention includes the oral use of non-absorbable polyamine agents and amine-related agents such as chitosan and cholestyramine to covalently bind and sequester potentially toxic carbonyl compound present in the diet. Veterinary, food processing and cosmetic applications of the present invention are also described.
Patent DE-69307717-D1 (DE)
Inventor: TIPLEY ROGER
IPC: G06F13/364
Filed: 1993-09-24
Granted: 1997-03-06
Abstract: Three prioritization schemes for determining which of several CPUs receives priority to become bus master of a host bus in a multiprocessor system, and an arbitration scheme for transferring control from one bus master to another. Each prioritization scheme prioritizes n elements, where a total of (n/2)x(n-1) priority bits monitors the relative priority between each pair of elements. An element receives the highest priority when each of the n-1 priority bits associated with that element points to it. In the arbitration scheme, the current bus master of the host bus determines when transfer of control of the host bus occurs as governed by one of the prioritization schemes. The arbitration scheme gives EISA bus masters, RAM refresh and DMA greater priority than CPUs acting as bus masters, and allows a temporary bus master to interrupt the current bus master to perform a write-back cache intervention cycle. The arbitration scheme also supports address pipelining, bursting, split transactions and reservations of CPUs aborted when attempting a locked cycle. Address pipelining allows the next bus master to assert its address and status signals before the beginning of the data transfer phase of the next bus master. Split transactions allows a CPU posting a read to the EISA bus to arbitrate the host bus to another device without re-arbitrating for the host bus to retrieve the data. The data is asserted on the host bus when it is idle even if the host bus is being controlled by another device.
Patent DE-69309082-D1 (DE)
Inventor: CEBULA DERYCK
IPC: A23G1/21
Filed: 1993-09-28
Granted: 1997-04-24
Abstract: Fat-containing products, especially chocolate, are formed in moulds at temperatures at or below 0  DEG C to provide unforced demoulding.
Patent DE-69309875-D1 (DE)
Inventor: HANSENNE ISABELLE
IPC: A61Q1/12
Filed: 1993-11-23
Granted: 1997-05-22
Abstract: The invention relates to cosmetic compositions for colouring (dyeing) the skin, characterised in that they contain, in a cosmetically acceptable medium, at least dihydroxyacetone and at least one thickening agent consisting of a crosslinked copolymer of acrylamide/2-acrylamido-2-methylpropanesulphonic acid which has been partially or totally neutralised.
Patent DE-69317122-D1 (DE)
Inventor: NIGRO ALBERTO
IPC: C07D249/12
Filed: 1993-11-06
Granted: 1998-04-02
Abstract: PCT No. PCT/EP93/03119 Sec. 371 Date May 11, 1995 Sec. 102(e) Date May 11, 1995 PCT Filed Nov. 6, 1993 PCT Pub. No. WO94/11357 PCT Pub. Date May 26, 1994Preparation of a 1,2,4-triazol-3-one compound substituted in positions 4 and 5 by an alkyl or aryl group and, optionally, in position 2 by an alkyl group, by reacting an ester a of carbamic acid N-substituted by an alkyl or aryl group with a hydrazide of an aliphatic or aromatic carboxylic acid, optionally N-substituted by an alkyl group, in the presence of a strong base.
Patent DE-69326810-D1 (DE)
Inventor: KEPLEY KEVIN PAUL
IPC: A61B18/00
Filed: 1993-08-05
Granted: 1999-11-25
Abstract: A drive for a phacoemulsification probe (13) includes a drive circuit (15) for supplying electrical power to the probe (13), circuitry (29) for sensing the electrical power supplied by the drive circuit (15) to the probe (13) and for supplying electrical signals indicative of the magnitude of the electrical power supplied. A manually operable input device (21) provides a signal indicative of the transducer power level desired by the user of the probe (13). A control circuit is responsive to the signal indicative of the desired transducer power level and to the signals indicative of the magnitude of the supplied electrical power for providing control signals to the drive circuit (15) to control the power applied in an efficient manner. The drive circuit (15) includes a totem-pole switch (31), responsive to at least one of the control signals, to apply power in a square-wave waveform, and a switching regulator (27) for supplying a supply voltage to the totem-pole switch (31). The totem-pole switch (31) has circuitry associated therewith which is responsive to one of the control signals to initially vary the frequency of the square-wave waveform. The regulator (27) is responsive to a second control signal (A) from the control circuit to vary the voltage supplied by the regulator (27) to the totem-pole switch (31) to control the amplitude of the square-wave waveform. The switching nature of this system substantially minimizes the power consumption of the drive circuit (15) as compared with conventional techniques. <IMAGE>
Patent DE-69328829-D1 (DE)
Inventor: WARANIS ROBERT PAUL
IPC: A61K47/18
Filed: 1993-03-29
Granted: 2000-07-13
Abstract: Disclosed herein is an aqueous, injectable rapamycin solution comprising 0.1 to 10 percent of a concentrate solution of rapamycin in N,N-dimethylacetamide, at concentrations of rapamycin ranging from 0.25 mg/ml to 100 mg/ml, in combination with a diluent solution consisting of 0.1 to 10 weight percent of one or more polyoxyethylene sorbitan esters, 10 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent water, wherein the concentration of rapamycin in he combined solution ranges from 0.05 mg/ml to 5.0 mg/ml. Also disclosed is an aqueous, injectable solution of rapamycin, said solution comprising rapamycin in 0.1 to 10 weight percent N,N-dimethylacetamide, 0.09 to 7.5 weight percent of one or more polyoxyethylene sorbitan esters, 9 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent of water, wherein the concentration of rapamycin in the solution ranges from 0.05 mg/ml to 5.0 mg/ml. Preferred aqueous, injectable rapamycin solutions are those wherein one polyoxyethylene sorbitan ester is present and the polyethylene glycol present is polyethylene glycol 300.
Patent DE-69401701-D1 (DE)
Inventor: STRONG HENRY LEE
IPC: C07B61/00
Filed: 1994-11-09
Granted: 1997-03-20
Abstract: Prodn. of cyclopropylnitrile (I) (i.e cyclopropane-carbonitrile) comprises mixing a 4-halo-butyronitrile (II), at least 0.25 moles (i.e molar equivs). of an inorganic salt (III) and a catalytic amt. of H2O in the presence of an aprotic polar solvent at 5-100[deg]C, and reacting the mixt. with an alkali metal base at the same temp. (III) is a Na, K or Li halide, sulphate or carbonate.
Patent DE-69418614-D1 (DE)
Inventor: WERNER TORSTEN
IPC: F41J13/00
Filed: 1994-09-26
Granted: 1999-06-24
Abstract: PCT No. PCT/SE94/00886 Sec. 371 Date Mar. 13, 1996 Sec. 102(e) Date Mar. 13, 1996 PCT Filed Sep. 26, 1994 PCT Pub. No. WO95/09342 PCT Pub. Date Apr. 6, 1995In a bullet trap for indoor shooting with small arms, which bullet trap, behind the targets, includes a vertically suspended curtain (1) made of rubber, and a vertically supported impact plate (3) made of steel and being spaced behind the curtain, the space between the curtain and the impact plate is enclosed by cover plates (4, 4', 5, 6) extending forwards from the side, upper and lower margins of the impact plate, covering the space between the impact plate and the curtain, whereby the latter is sealingly attached to the front edges of the cover plates through steel profiles (9), attached to the cover plates by screwing through the curtain. The enclosed space is continuously evacuated by connected fan means (10) and an interconnected filter (12) to prevent that lead containing dust, which is set free upon the impact of the bullets in the bullet trap, is distributed to the air and the shooting premises.
Patent DE-69424266-D1 (DE)
Inventor: BOARDMAN JAMES
IPC: C03B23/023
Filed: 1994-12-16
Granted: 2000-06-08
Abstract: A furnace (1) is provided for the heating of glass sheets (20,21) to be bent, whereby precise control of the temperature profile across a sheet may be achieved, resulting in improved control over the shape to which the sheet is bent. The furnace has at least one differential heating zone (S3,S4) provided with a plurality of main heating elements (37), characterised by a shield (35, 45, 115, 125), associated with said furnace and located in said zone (S3,S4) on the same side of a glass sheet to be bent as said heating elements (37), for directing heat radiated by said heating elements (37) whereby a controlled differential heating of the glass may be achieved. The invention also relates to a method of bending a glass sheet, and to a glass sheet bent in such a furnace. <IMAGE>
Patent DE-69429631-D1 (DE)
Title: Conotoxinpeptide
Inventor: OLIVERA BALDOMERO M
IPC: C12N15/12
Filed: 1994-10-19
Granted: 2002-02-14
Abstract: The invention is directed to A-lineage conotoxin peptides, which are conotoxin peptides that have strong homology in the signal sequence and the 3'-untranslated region of the genes coding for these peptides to the sequences in the  alpha -conotoxin peptides. The A-lineage conotoxin peptides include the  alpha -conotoxin peptides, the  alpha -conotoxin-like peptides and the  kappa -conotoxin peptides, described further below. The  alpha -conotoxin-peptides generally share a "core" sequence motif. This core sequence is termed the  alpha 3/5 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:1). The  alpha -conotoxin-like peptides generally share a core sequence termed the  alpha 4/7 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:2). The  kappa -conotoxin peptides generally have a core sequence termed the  kappa 7/2/1/3 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Cys-Xaa-Cys-Xaa-Xaa-Xaa-Cys (SEQ ID NO:3).
Patent DE-69430796-D1 (DE)
Inventor: D AMATO ROBERT
IPC: A61K31/404
Filed: 1994-02-24
Granted: 2002-07-18
Abstract: Thalidomide for treating solid and blood-borne tumours, wherein said tumour is a breast cancer, leukaemia, neoplastic disease of the bone marrow, Kaposi's sarcoma, hemangioma, rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, osteosarcoma, acoustic neuroma, neurofibroma, trachoma, or pyogenic granuloma;and for treating ocular neovascular disease, macular degeneration, proliferative vitreoretinopathy, retrolental fibroplasia, psoriasis, Crohn's disease, diabetic retinopathy, Osler-Weber-Rendu disease, hereditary hemorrhagic telangienctasia or osteoarthritis.
Patent DE-69433231-D1 (DE)
Inventor: TYMES LAROY
IPC: H04J13/00
Filed: 1994-03-30
Granted: 2003-11-20
Abstract: A packet data transmission system is used to link a number of remote hand-held data-gathering units such as bar code readers to a central computer. Data packets are sent from the remote units by a spread spectrum RF link to intermediate base stations, then sent by the base stations to the central computer by a serial link. The remote hand-held units initiate an RF exchange to and from the base stations, receiving only during a time window following a transmission from the remote unit. The base stations cannot initiate an exchange with the remote units, but instead send data to the remote units only as part of the exchange. To alert a remote unit when a message is waiting at a base station to be sent to a particular unit, some of the acknowledge (base-to-remote) packets sent by the base station may contain an identification such as a list of all remote units (identified by ID number) which have messages waiting. Alternatively, a bit map can be used to identify these remotes. These base-to-remote packets with the identification of remotes with messages waiting are called "announcements." Each remote unit (if not engaged in regular exchanges for a time interval) periodically listens (activates its receiver) to receive an announcement packet containing such a list or bit map and decodes this announcement to see if it has a message waiting. If so, this remote unit then sends a transmit packet so the base can send the waiting message in an acknowledge packet.
Patent DE-69512589-D1 (DE)
Inventor: MAYNE JAMES T
IPC: A61K31/44
Filed: 1995-08-10
Granted: 1999-11-11
Abstract: A method of treating diseases caused by sebaceous gland disorders, in humans and animals, which comprises administering to said humans and animals a composition comprising a sebaceous gland secretion inhibiting amount of an active compound comprising an acyl coA cholesterol acyl transferase (ACAT) inhibitor or prodrug therefor. A composition for use in treating diseases caused by sebaceous gland disorders such as acne in humans and animals which comprises a sebaceous gland secretion inhibiting amount of an acyl coA cholesterol acyl tanferase (ACAT) inhibitor or prodrug therefor and, optionally, a pharmaceutically acceptable carrier.
Patent DE-69518808-D1 (DE)
Inventor: PARADAS JOSE
IPC: C05G1/00
Filed: 1995-04-25
Granted: 2000-10-19
Abstract: A method for making a substrate by preparing a base including a predetermined amount of a biomineral material synthesised by at least one or a part of a living structure selected from the plant kingdom, the animal kingdom and/or microorganisms; and converting the base into an inactivated biomineral substrate having a texture predetermined according to a selected extemporaneous use, particularly as heat insulation, sound insulation, a filter, an acoustic membrane, a decorative wall, a fabric or a yarn, or according to a given medical and/or paramedical use. In an alternative embodiment, the method provides a natural and/or artificial soil nutrient, and said base is converted into an inactivated nutrient mineral substance with a composition and texture predetermined according to the requirements of the soil type in question. In a further alternative embodiment, said base is converted into an inactivated mineral material with a predetermined texture for use as a filler.
Patent DE-69527835-D1 (DE)
Inventor: SVENDSEN ALLAN
IPC: C12N9/20
Filed: 1995-02-22
Granted: 2002-09-26
Abstract: The present invention relates to a method of preparing a variant of a parent lipolytic enzyme, comprising (a) subjecting a DNA sequence encoding the parent lipolytic enzyme to random mutagenesis, (b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and (c) screening for host cells expressing a mutated lipolytic enzyme which has a decreased dependance to calcium and/or an improved tolerance towards a detergent or a detergent component as compared to the parent lipolytic enzyme.
Patent DE-69533298-D1 (DE)
Inventor: AKIMOTO KENGO
IPC: A23L29/00
Filed: 1995-05-12
Granted: 2004-09-02
Abstract: An agent for the prevention or alleviation of allergy symptoms contains as an effective component a dioxabycyclo[3.3.0]octane derivative represented by the following general formula (I): <CHEM> where R<1>, R<2>, R<3>, R<4>, R<5> and R<6> each independently represent a hydrogen atom or alkyl group of 1-3 carbon atoms, or R<1> and R<2> and/or R<4> and R<5> together represent a methylene or ethylene group, and n, m and 1 represent 0 or 1. An agent for the prevention or alleviation of allergy symptoms also contains as an effective component an antioxidant in addition to the dioxabicyclo[3.3.0]octane derivative.
Patent DE-69603875-D1 (DE)
Inventor: MENIERE JEROME
IPC: G08B21/08
Filed: 1996-11-13
Granted: 1999-09-23
Abstract: PCT No. PCT/FR96/01789 Sec. 371 Date May 12, 1998 Sec. 102(e) Date May 12, 1998 PCT Filed Nov. 13, 1996 PCT Pub. No. WO97/18542 PCT Pub. Date May 22, 1997A system for monitoring a swimming pool to prevent drowning accidents includes sensing devices (D1, D2, D3) for providing electrical signals forming images of bodies immersed in the pool water. Appropriate hardware (10) digitizes the resulting images, and the digital image data is compressed and stored at a series of times. Digitized images of a single body are compared at a series of times. The nature of a body, the path of the body and changes in the position of the body are estimated on the basis of the series of images; and an alarm is activated should the path or movement of the body being observed give cause for concern.
Patent DE-69605564-D1 (DE)
Inventor: KLAWITTER JEROME JOHN
IPC: A61F2/42
Filed: 1996-09-16
Granted: 2000-01-13
Abstract: A joint prosthesis designed to replace the carpometacarpal joint of the human thumb. A first element which replaces the articular portion of the first metacarpal mates with a second element which replaces the articular portion of the trapezium. Articulation of the said first and second elements is provided by abutting toroidal mating surfaces which are complementary sections of the surfaces of identical toruses having center hole diameters equal to the diameters of the tubes. Contact of the mating surfaces is only along a pair of curved lines in perpendicular planes providing open spaces for lubrication of the joint by biological fluids.
Patent DE-69610851-D1 (DE)
Inventor: MANTEGANI SERGIO
IPC: A61K31/4465
Filed: 1996-09-16
Granted: 2000-12-07
Abstract: PCT No. PCT/EP95/04075 Sec. 371 Date Mar. 31, 1998 Sec. 102(e) Date Mar. 31, 1998 PCT Filed Sep. 16, 1996 PCT Pub. No. WO97/13769 PCT Pub. Date Apr. 17, 1997A Disubstituted piperidine compounds of formula (I), wherein R1 is hydrogen; bromo; chloro; a linear or branched C1-C5 alkyl group; a linear or branched C1-C5 alkoxy group; or an optionally substituted phenyl group; R2 is hydrogen, a linear or branched C1-C5 alkyl group or an optionally substituted phenyl group; X is CH2, C=O, CHOH or C=NOH; R3 is hydrogen or a linear or branched C1-C5 alkyl group; Y is a (CH2)n group in which n is an integer from 0 to 4, CHOH, C=O or CH-A wherein A is an optionally substituted phenyl group; A is an optionally substituted phenyl group; W is hydrogen or hydroxy; stereoisomers thereof and their pharmaceutically acceptable salts. The compounds possess selective neuroprotective activity and are useful in the treatment of an acute or a degenerative CNS disease. A process is described for preparing the compounds and pharmaceutical compositions containing them.
Patent DE-69611343-D1 (DE)
Inventor: DE LACHARRIERE OLIVIER
IPC: A61K33/244
Filed: 1996-10-14
Granted: 2001-02-01
Abstract: Use of at least one salt in the manufacture of or in cosmetic, pharmaceutical or dermatological compositions for: (i) treating pain associated with at least one cutaneous disorder selected from shingles, post-zoster, burns, seborrheic eczema, demodiciosis, cutaneous ulcers and fibrosis; (ii) controlling hypertrophic cicatrisation; and/or (iii) treating acne rosacea. (I) is selected from salts of yttrium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, tin, zinc, manganese, cobalt, barium and strontium.
Patent DE-69611933-D1 (DE)
Inventor: GAMBASSI STEFANO
IPC: E03D9/00
Filed: 1996-12-06
Granted: 2001-04-05
Abstract: Method for the collection and the disposal of the dejections from patients confined to bed comprising the use of a film of polyvinyl alcohol to line the collection pad and the treatment of the wrapper containing the dejection with hot water at a temperature not lower than 60  DEG C simultaneously submitting it to a mechanical mincing. The suspension thus obtained can be disposed of through the sewer system. The apparatus to implement the method comprises a container (10) with a blade mixer (12), in which the wrapper is immersed with hot water produced by an external heater (16).
Patent DE-69625912-D1 (DE)
Inventor: FIDDES JAMES
IPC: G01N33/68
Filed: 1996-10-04
Granted: 2003-02-27
Abstract: Method for assessing the activity of a test substance as a K+ channel agonist or for mitogenic activity. Fibroblasts are cultured in a test medium which is free of aminoglycoside antibiotics, the medium is supplemented with serum or serum substitute and the test substance, and the response of the supplemented cells to the test substance is assessed.
Patent DE-69628158-D1 (DE)
Inventor: TAKEMURA MAKOTO
IPC: C07D401/04
Filed: 1996-02-06
Granted: 2003-06-18
Abstract: The present invention provides an antibacterial compound useful as medicines, animal drugs, fisheries drugs or antibacterial preservatives and to an antibacterial agent or preparation which contains the same, more particularly a compound which possesses high safety and excellent activity against a broad range of bacterial species including quinolone-resistant strains. A quinolone derivative of the following formula (I) which has a group derived from the heterocyclic spiro-compound at the 7-positioned R<2> and the halogenocyclopropyl group at the N1-position, prefereably a compound of pure isomer, and an antibacterial agent containing the derivative compound. <CHEM>
Patent DE-69636327-D1 (DE)
Inventor: VERKAART H
IPC: B01D36/00
Filed: 1996-10-18
Granted: 2006-08-17
Abstract: A system for the collection of physiological fluids includes a vacuum source (14) that is controlled to provide low vacuum as a function of whether fluids are entering the system. The suction wand and associated tubing are made of thin flexible materials, and the pressures employed do little damage to the collected fluids.
Patent DE-69637812-D1 (DE)
Inventor: BETSOU FOTINI
IPC: C12N9/88
Filed: 1996-06-25
Granted: 2009-03-05
Abstract: Purified nucleic acids comprising a nucleotide sequence encoding an immunogenic polypeptide of adenyl cyclase-haemolysin (AC-Hly), which induces formation of protective antibodies against an infection by a bacteria selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica when the nucleic acid or polypeptide is administered to a human or animal host. The nucleic acids are useful, for example, to induce a protective immune response in a host against infection by a bacteria selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica.